Optimal Duration and Monitoring of Iron Therapy After Ferritin Reaches 30 µg/L

Target Ferritin Levels

In the absence of inflammation, the recommended ferritin target is ≥ 50 ng/mL for all patients, regardless of sex. 1
For patients with inflammatory bowel disease, a higher ferritin goal of up to 400 µg/L is advised to prevent iron‑deficiency recurrence over the next 1–5 years. 2

After ferritin reaches 30 µg/L, iron supplementation should be continued for at least 3 months to raise stores to the ≥ 50 ng/mL target and reduce the risk of rapid recurrence. 1
Post‑treatment iron stores are directly linked to the time before iron deficiency recurs; higher ferritin levels after therapy prolong the recurrence‑free interval. 2

Laboratory re‑evaluation of iron parameters should be performed 4–8 weeks after the last intravenous infusion. 1
Hemoglobin typically rises 1–2 g/dL within 4–8 weeks, with the initial increase observed as early as 1–2 weeks after infusion. 1
A single total‑dose infusion may be sufficient when the underlying cause of iron loss has been eliminated. 1

Monitoring schedule: check iron status every 3 months for the first year after correction, then every 6–12 months thereafter. 2
Re‑initiate therapy if ferritin falls below 100 µg/L. 2
Re‑initiate therapy if hemoglobin drops below 12 g/dL in women or 13 g/dL in men. 2

Premature discontinuation at ferritin 30 µg/L leaves inadequate stores and leads to rapid recurrence within months rather than years. 2
Ignoring ongoing iron losses (e.g., heavy menstrual bleeding, gastrointestinal bleeding, malabsorption) necessitates repeated iron administrations, with frequency dictated by the severity of loss. 1
Testing too early (within 4 weeks of a total‑dose infusion) can produce spurious iron‑parameter results due to circulating iron interference. 1
Overlooking functional iron deficiency: when ferritin appears adequate but transferrin saturation is < 20 %, functional deficiency may persist and requires continued treatment. 1